Belvedere Trading
ATXS

Belvedere Trading’s Astria Therapeutics ATXS Stock Holding History

Belvedere Trading’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-8,500
Closed -$120K – 689
2024
Q1 		$120K Buy
+8,500
New +$106K ﹤0.01% 406

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Belvedere Trading's ATXS Position: Q2 2024 in Review

Belvedere Trading sold out of Astria Therapeutics (ATXS) in Q2 2024, closing a stake of 16,036 shares — an estimated $226K sold.

Belvedere Trading first reported a position in ATXS in Q1 2024 and held it in 1 quarter. The position peaked at $226K in Q1 2024. 100 funds tracked by Wall St. Rank hold ATXS as of Q2 2024.

  • Belvedere Trading reported no remaining Astria Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Belvedere Trading sold 16,036 Astria Therapeutics shares in Q2 2024, an estimated $226K.
  • Belvedere Trading first reported a position in Astria Therapeutics in Q1 2024 and held it in 1 quarter.
  • Belvedere Trading's Astria Therapeutics position peaked at $226K in Q1 2024.
  • 100 funds tracked by Wall St. Rank held Astria Therapeutics as of Q2 2024.

Based on Belvedere Trading's 13F filing for Q2 2024, filed 9 Aug 2024.